Deborah Weitzman Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 6 days, 20 hours ago
Deborah Weitzman has an estimated net worth of at least $28.4 million*, as of Sept. 9, 2026. They own 78,590 shares of CAH stock. They have sold 72,075 shares of CAH stock since 2021, for an estimated $9.4 million.
Deborah Weitzman $CAH SEC Form 4 Insider Trading
Deborah Weitzman has filed a total of 6 insider trades in $CAH since 2021. Their most recent trade was a sale of 6,665 shares, made on Aug 18, 2026. Their largest trade was a sale of 36,642 shares, made on Nov 27, 2023. We estimate that they now own 78,590 shares of $CAH, worth an estimated $18.9 million.
Insider Trading at $CAH
There have been a total of 81 insider trades reported at $CAH since 2021, with 874 shares purchased and 1.1 million shares sold. The most active insider traders in $CAH stock have been Jason M. Hollar, Jessica L Mayer, and Ola M Snow. The most recent trade was a sale of 21,407 shares reported by Jason M. Hollar (Chief Executive Officer), made on Aug 18, 2026.
History of Insider Stock Trades by Deborah Weitzman
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
CAH
|
Sale | 6,665 | Aug 18, 2026 | Aug. 24, 2026, 7:20 a.m. |
|
CAH
|
Sale | 408 | Aug 18, 2026 | Aug. 24, 2026, 7:20 a.m. |
|
CAH
|
Sale | 281 | Aug 18, 2026 | Aug. 24, 2026, 7:20 a.m. |
|
CAH
|
Sale | 21,367 | Aug 20, 2025 | Aug. 20, 2025, 4:12 p.m. |
|
CAH
|
Sale | 36,642 | Nov 27, 2023 | Nov. 29, 2023, 10:14 a.m. |
|
CAH
|
Sale | 6,712 | Aug 28, 2023 | Aug. 29, 2023, 4:21 p.m. |
$CAH Executives and Stock Owners with Insider Trades
-
Jason M. Hollar, Chief Executive Officer
-
Jessica L Mayer, Chief Legal/Compliance Officer
-
Ola M Snow, Chief Human Resources Officer
-
Stephen M Mason, CEO, GMPD Segment
-
Aaron E Alt, Chief Financial Officer
-
Michelle D. Greene, Chief Information Officer
-
Mary C. Scherer, Chief Accounting Officer
-
Deborah Weitzman, CEO, PSS Segment
-
Stephen M Mason, CEO, Medical Segment
-
Deborah Weitzman, CEO, Pharmaceutical Segment
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.